Basilea reports presentation of data on clinical oncology

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Basilea reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting
  • Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment
  • PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models

BASEL, Switzerland, April 21, 2016 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that preclinical data on the oncology drug candidates BAL101553 and BAL3833 were presented at the American Association for Cancer Research (AACR) annual meeting in New Orleans, USA, April 16-20, 2016. The tumor-checkpoint controller BAL101553 is currently in Phase 1/2a clinical development, and the panRAF/SRC kinase inhibitor BAL3833 is currently in Phase 1.

At the AACR meeting, preclinical data were presented demonstrating anti-cancer activity of BAL101553 against glioblastoma multiforme (GBM), a highly malignant form of brain cancer that has very limited treatment options and often has poor prognosis. BAL101553 efficiently penetrates the brain in preclinical models and has previously demonstrated anti-cancer activity in treatment-refractory solid tumor models alone and in combination with radiotherapy. 1 The data presented at the AACR were generated by the group of Prof. Jann N. Sarkaria (Mayo Clinic, Rochester) and demonstrate statistically significant single agent activity in a panel of in vivo GBM models after daily, oral administration, including models refractory to temozolomide (TMZ) and radiotherapy, the standard of care for newly diagnosed GBM. Moreover, using a model with reduced sensitivity to both radiotherapy and TMZ, BAL101553 combined with either radiotherapy alone or radiotherapy and TMZ together provided additional benefit, leading to statistically significant prolongation of survival as compared to the standard of care treatment regimens. These data indicate that BAL101553 alone or in combination may provide a survival extension in GBM patients, potentially offering an alternative therapeutic option in this area of high medical need. BAL101553 is currently being evaluated in phase 1/2a clinical trials with both oral and i.v. administration schedules.

In a late-breaking research session, the groups of Prof. Caroline Springer (The Institute of Cancer Research, London) and Prof. Richard Marais (Cancer Research UK Manchester Institute, University of Manchester) reported that the novel panRAF/SRC kinase inhibitor BAL3833, also known as CCT3833, has anti-cancer activity in KRAS-driven in vitro and in vivo tumor models via inhibition of the RAF and SRC family kinases. KRAS is an important driver of tumor cell growth, with high rates of KRAS mutation found in several major cancer types, including pancreatic, colorectal and non-small-cell lung cancer. BAL3833 inhibits mutant BRAF as well as the CRAF and SRC protein kinases and was initially developed to address the increasing medical need of melanoma patients who progress on current mutant BRAF pathway inhibitors. The data presented show that BAL3833 may also be effective in non-melanoma KRAS-mutant cancers, potentially providing a new therapeutic option for these patients. Orally administered BAL3833 is currently being explored in a phase 1 clinical study in patients with solid tumors, including BRAF-mutant and BRAF inhibitor-resistant melanomas.

BAL1011553 poster at AACR 2016 The novel tubulin-binding 'tumor checkpoint controller' BAL101553 has anti-cancer activity alone and in combination treatments across a panel of GBM patient-derived xenografts - Ann C. Mladek, Jenny L. Pokorny, Heidi Lane, Felix Bachmann, Mark A. Schroeder, Katrina K. Bakken, Brett L. Carlson, Paul A. Decker, Jeanette E. Eckel-Passow, Jann N. Sarkaria; Abstract 4781
BAL3833 poster at AACR 2016 Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models - Grazia Saturno, Filipa Lopes, Maria Romina Girotti, Ion Niculescu-Duvaz, Dan Niculescu-Duvaz, Alfonso Zambon, Lawrence Davies, Louise Johnson, Natasha Preece, Amaya Viros, Malin Pedersen, Robert McLeary, Ruth Knight, Rebecca Lee, Denys Holovanchuk, Alberto Fusi, Paul Lorigan, Nathalie Dhomen, Richard Marais, Caroline Springer; Abstract LB-212

For further information please visit www.aacr.org .

About BAL101553

Basilea's oncology drug candidate BAL101553 (the prodrug of the small-molecule BAL27862) is being developed as a potential therapy for diverse cancers, including tumor types unresponsive to standard therapeutics. BAL101553 is currently undergoing clinical evaluation in patients with advanced solid tumors as an i.v. (phase 2a) and oral (phase 1) formulation. It has shown evidence of clinical anti-tumor activity in a phase 1 study during which the maximum tolerated dose was established. 2 In previous pre-clinical studies, the drug candidate demonstrated in-vitro and in-vivo activity against diverse treatment-resistant cancer models, including tumors refractory to conventional approved therapeutics and radiotherapy. 1, 3, 4 BAL101553 efficiently distributes to tumors and to the brain, with cytotoxic effects in glioblastoma (brain tumor) cell lines. 5 The active moiety BAL27862 binds the colchicine site of tubulin with distinct effects on microtubule organization, resulting in the formation of the "spindle assembly checkpoint" which promotes tumor cell death. 6 Potential biomarkers are being tested in early clinical studies in order to optimize dose selection and identify cancer patient groups more likely to respond.

About BAL3833

BAL3833 (also known as CCT3833) is an orally available small-molecule panRAF/SRC kinase inhibitor targeting cell proliferation signaling pathways that are associated with tumor growth and resistance development to current therapies. It is the lead compound of a series of kinase inhibitors in-licensed by Basilea in April 2015 under an agreement with The Institute of Cancer Research, London, Cancer Research Technology, the Wellcome Trust, and The University of Manchester. BRAF is mutated in a range of cancers including melanomas, colorectal and serous ovarian cancer. Data from preclinical studies suggest that this class of compounds, targeting the BRAF, CRAF and SRC family kinases, are active in diverse patient-derived models resistant to standard BRAF as well as MEK inhibitor therapies. 7 BAL3833 has progressed into a phase 1 study in adult patients with advanced solid tumors including BRAF-mutant and BRAF inhibitor-resistant melanomas. The compound originates from research at The Institute of Cancer Research and the Cancer Research UK Manchester Institute, by scientists funded by Cancer Research UK and the Wellcome Trust.

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com .

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD Head Corporate Communications & Investor Relations +41 61 606 1102 media_relations@basilea.com investor_relations@basilea.com

This press release can be downloaded from www.basilea.com .

References

1 A. Broggini-Tenzer et al. The novel microtubule-destabilizing drug BAL101553 (prodrug of BAL27862) sensitizes a treatment refractory tumor model to ionizing radiation. EORTC-NCI-AACR symposium 2014, abstract 202

2 L. R. Molife et al. Phase 1/2a trial of the novel microtubule inhibitor BAL101553 in advanced solid tumors: Phase 1 completed. American Society of Clinical Oncology (ASCO) annual meeting 2014, abstract 2562

3 G. E. Duran et al. In vitro activity of the novel tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and ovarian cancer variants selected for resistance to taxanes. American Association for Cancer Research (AACR) annual meeting 2010, abstract 4412

4 F. Bachmann et al. BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab. American Association for Cancer Research (AACR) annual meeting 2014, abstract 831

5 A. Schmitt-Hoffmann et al. BAL27862: a unique microtubule-targeted agent with a potential for the treatment of brain tumors. AACR-NCI-EORTC symposium 2009, abstract C233

6 F. Bachmann et al. BAL101553 (prodrug of BAL27862): the spindle assembly checkpoint is required for anticancer activity. American Association for Cancer Research (AACR) annual meeting 2015, abstract 3789

7 M. R. Girotti et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma, Cancer Cell 2015 (27), 85-96

Press release (PDF) http://hugin.info/134390/R/2005388/740703.pdf

HUG#2005388

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 157

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 161

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
LA Hospitals Shine in Pulmonary Excellence Nationwide

Updated Category News Views 135

Los Angeles Community Hospitals' Recent Recognition You ever stroll into a hospital and wonder if you’re really getting the best care? Well, the folks over at Los Angeles Community Hospitals, covering LA, Norwalk, and Bellflower, just got a big nod from Healthgrades—yeah, the site everyone's checking to find decent healthcare options. They’ve landed among the top...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 69

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 87

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 183

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 242

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 132

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 217

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 148

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading

Top 5 Most Recently Viewed Articles

Compugen's Q4 2025 Results: Is CGEN Set for a Rebound?

Updated Category News Views 168

Compugen Ltd. (NASDAQ: CGEN) is gearing up for its fourth quarter and full-year 2025 financial results set to drop on March 2, 2026, before U. S. markets open. You know how it goes—traders are already sizing up this number drop, trying to parse out if there’s any upside left or if it's just another 'waiting for Godot' situation. Compugen has been riding the waves of...

Continue Reading
Procyon Partners Appoints Rich Franchella to Propel Growth Strategy

Updated Category News Views 384

Procyon Partners' Strategic Growth Through Leadership Appointment Procyon Partners is excited to announce a significant addition to its leadership team with the appointment of Rich Franchella as the Senior Vice President of Business Development. This newly established role is aimed at catalyzing the firm’s growth trajectory and is set to bolster its efforts in...

Continue Reading
SMC Entertainment Expands Horizons With Bateau Acquisition

Updated Category News Views 162

SMC Entertainment Enhances Its Market Position SMC Entertainment, Inc. has taken a significant step in broadening its reach within the financial services sector by acquiring Bateau Asset Management. This strategic move paves the path for SMC to tap into the Australian and Southeast Asian markets, expanding its footprint in the dynamic world of fintech. An Overview of...

Continue Reading
Dustin Moskovitz Expands Asana Holdings with Major Purchase

Updated Category News Views 503

Dustin Moskovitz Expands His Investment in Asana Facebook co-founder Dustin A. Moskovitz, who currently holds the position of Director at Asana, Inc., has recently made headlines by increasing his stake in the company through the acquisition of 225,000 shares. This move highlights his ongoing commitment to the growth and success of Asana. Details of the Share Purchase The...

Continue Reading
GDMining's Innovative Cloud Mining Service Redefines Accessibility

Updated Category News Views 146

GDMining Expands Global Reach with Free Cloud Mining Service The cryptocurrency market is constantly evolving, and GDMining is leading the charge. This innovative platform offers an exciting opportunity for individuals around the globe to earn income from home through its unique cloud mining services. What sets this initiative apart is that it requires no initial...

Continue Reading